Horizon Therapeutics plc Named to the Seramount Inclusion Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Stifel Reiterates Buy Rating on Horizon Therapeutics (HZNP) Following Results
November 2, 2022 11:51 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $138.00 price target on Horizon Therapeutics (NASDAQ: HZNP) as results showed Tepezza sales are on the mends, with peak guidance raised.
The analyst commented, "Coming off a challenging 1H22 Tepezza transitionary period, HZNP returned to solid performance, reporting revenues... More
